Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer

[Image: see text] The epidermal growth factor receptor (EGFR) is a validated therapeutic target for triple-negative breast cancer (TNBC). In the present study, we synthesize novel adamantanyl-based thiadiazolyl pyrazoles by introducing the adamantane ring to thiazolopyrazoline. On the basis of loss...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ACS Omega
Auteurs principaux: Sebastian, Anusha, Pandey, Vijay, Mohan, Chakrabhavi Dhananjaya, Chia, Yi Ting, Rangappa, Shobith, Mathai, Jessin, Baburajeev, C. P., Paricharak, Shardul, Mervin, Lewis H., Bulusu, Krishna C., Fuchs, Julian E., Bender, Andreas, Yamada, Shuhei, Basappa, Lobie, Peter E., Rangappa, Kanchugarakoppal S.
Format: Artigo
Langue:Inglês
Publié: American Chemical Society 2016
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6044684/
https://ncbi.nlm.nih.gov/pubmed/30023509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.6b00251
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires